Review times and adverse events for cardiovascular devices
نویسندگان
چکیده
منابع مشابه
Antidepressants and cardiovascular adverse events: A narrative review
BACKGROUND Major depression or deterioration of previous mood disorders is a common adverse consequence of coronary heart disease, heart failure, and cardiac revascularization procedures. Therefore, treatment of depression is expected to result in improvement of mood condition in these patients. Despite demonstrated effects of anti-depressive treatment in heart disease patients, the use of some...
متن کاملAssociation between antipsychotics and cardiovascular adverse events: A systematic review.
Objective: Determine whether there is an association between the risk of cardiovascular adverse events and the use of antipsychotic agents. Method: Analysis of original articles retrieved from the following databases: LILACS, PubMed, Cochrane Controlled Trials Clinical Data Bank (CENTRAL) and PsycINFO, without language restriction, dated until November 2015. After screening of 2,812 studies,...
متن کاملClinical Review, Adverse Events
1.1 Background Carbamazepine (CBZ) is an anticonvulsant with FDA-approved indications in epilepsy, bipolar disorder and neuropathic pain. CBZ is associated with Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), closely related serious cutaneous adverse drug reactions that can be permanently disabling or fatal. Other anticonvulsants, including phenytoin, phenobarbital, and lam...
متن کاملReporting of Cardiovascular Medical Device Adverse Events to Pharmaceuticals and Medical Devices Agency, Japan☆
BACKGROUND Marketing authorization holders (MAHs) are obligated to report adverse events (AEs) within 15 days (some cases 30 days) to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. METHODS To analyze the timeliness of AE reporting to the PMDA, 6610 reports for five categories of cardiovascular devices were retrieved. Two durations were calculated: (1) time from the date the A...
متن کاملLipid Management Strategies for the Prevention of Adverse Cardiovascular Events
Accessible online at: www.karger.com/hed As the leading cause of death and a tremendous source of morbidity worldwide [1], atherosclerotic coronary artery disease (CAD) and its treatment and prevention represent one of the greatest challenges facing health care. Aggressive efforts at educating the public about CAD and identifying high-risk individuals as part of primary prevention of CAD are ne...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biomedical Engineering
سال: 2017
ISSN: 2157-846X
DOI: 10.1038/s41551-016-0013